Insilico Medicine debuts on HKEX in record AI biotech IPO

AI‑driven drug discovery firm Insilico Medicine listed on the Hong Kong Stock Exchange under code 03696.HK, raising about HK$2.28 billion in what is described as Hong Kong’s largest biotech IPO of 2025. The shares were priced at HK$24.05 and opened around HK$35, valuing the company at roughly HK$19.5 billion.([prnewswire.com](https://www.prnewswire.com/news-releases/qiming-venture-partners-insilico-medicine-successfully-lists-on-hong-kong-stock-exchange-302650996.html?utm_source=openai))